| GE Healthcare discusses new drug possibilities | Posted on 04/06/2009 in Scientific GE Healthcare has discussed details of a new radiopharmaceutical agent following its approval by the Food and Drug Administration (FDA).
The new drug application (NDA) for the company's DaTSCAN Ioflupane I123 injection was accepted under the terms of a priority review and a spokesman for the group has since commented on the product.
Don Black, managing director and head of research and development for the GE Healthcare Medical Diagnostics, said the firm was pleased that the offering was moving ahead.
"Acceptance of the NDA filing for priority review is an important milestone for GE Healthcare and we will continue to work with the FDA with the objective of making DaTSCAN available," he added.
The agent is designed for use in the detection of loss of functional nigrostraiatal dopaminergic neurons, which can form one of the signs of neurodegeneration.
Last week, GE Healthcare announced it had successfully installed its Discovery NM 530c nuclear cardiology camera in facilities based in New York, Ottawa, Zurich and Pisa.
 Other news stories from 04/06/2009
Read more in the Zenopa News Archive
How this news is generated
|  |
|
